The aim of this study was to determine the production of insulin-like growth factor binding proteins (IGFBP) and the role of the IGFBP-3 in human normal (n •= 2) and osteoarthritic (OA) articular cartilage (n = 14) explants. Binding proteins were studied in the medium by Western ligand blotting and Western blotting. Proteoglycan synthesis under insulin-like growth factor I (1GF-I) stimulation was studied after a pulse of "SOJ~ in the presence or absence of added IGFBP-3. Osteoarthritic explants released a doublet of IGFBPs with a 39/43 kDa M, corresponding to the binding protein 3. Constitutive production from unstimulated OA cartilage was higher than from normal cartilage. IGF-I induced a 20-fold increase and IL-1 a 2-fold increase in IGFBP-3 release. A minor band around 30 kDa was also detectable. Studies of proteoglycan (PG) synthesis showed that the majority of OA cartilage explant samples responded weakly to IGF-I (100 ng/ml) stimulation (+33%), while the others were high responders (+180%). Co-incubation of IGF-I with recombinant (r) IGFBP-3 did not affect the rate of PG synthesis. However, while pre-incubation with rIGFBP3 for 72 h did not change the rate of PG synthesis in the high-responder group, it strongly increased PG synthesis in the low-responder group. This study demonstrates that the ability of IGF-I to enhance proteoglycan synthesis varied among the OA samples and may in part be dependent on the local level of IGFBP-3. This implies pathophysiological considerations in the limits of IGF-I action during the OA process.
ARTICULAR cartilage synthesizes large hydrated proteoglycans (PGs) which are essential for resisting compressive loads. These PGs are continuously being turned over within the matrix, and the regulation of that process is essential for the maintenance and function of healthy articular cartilage [1] .
Osteoarthritis (OA) is characterized by slow progressive destruction of cartilage matrix. Despite an increased synthesis of PG in the early stages of the disease [2] , net depletion of aggrecan ensues [2] . The mechanisms involved in the degradation of the cartilage matrix are not completely understood. It has been postulated that OA results from disruption of the equilibrium between synthesis and degradation of matrix molecules in which the degradative process eventually exceeds the reparative one, leading to a total loss of cartilage and eburnation of bone. Interleukin-1 (IL-1) is thought to be one of the main cytokines contributing to loss of the cartilage matrix as it increases the proteolytic activity of metalloproteinases [3, 4] , and inhibits the synthesis of collagen type II and of PG [5, 6] . During the OA process, attempts to repair the degenerative lesions have been observed and this has led to the study of factors that can stimulate cartilage repair. Insulin-like growth factor I (IGF-I) is known to be a major growth factor for the stimulation of cartilage PG synthesis [7] [8] [9] . IGF-I is essential to maintain in vivo the PG synthesis in anatomically intact murine cartilage in culture [10] . IGF-I can also increase the production of collagen type II and DNA synthesis [11] , and can counterbalance the deleterious effect of IL-1 on PG synthesis [12] . Moreover, IGF-I appears to be a differentiating factor that maintains the production of collagen type II mRNA and prevents the synthesis of type I collagen [13] .
However, with time, this anabolic response is unable to counterbalance the process of cartilage matrix degradation. This failure in anabolic response is not due to a decrease in cartilage IGF-I content, since there is an increased expression of IGF-I mRNA in OA cartilage [14] . Specific receptors (type 1 receptor) for IGF-I have been isolated on the chondrocyte membrane [15, 16] , and immunohistochemical study reveals' an increase in type 1 receptor level in OA cartilage as well as an increased binding capacity towards IGF-I compared with normal cartilage [16] . However, damaged cartilage (especially arthritic cartilages) often show unresponsiveness to IGF-I stimulation, with respect to maintenance of PG or protein synthesis [16] [17] [18] .
In view of these data, one may suspect that IGF-I action in cartilage is limited by other factors. The functions and the bioavailability of IGF-I may be modulated by binding proteins (BPs) [19] . Six BPs with an affinity for IGF-I have been isolated. In the serum, IGF-I is bound to IGFBP (notably IGFBP-3) and an acid-labile glycoprotein to form a 150 kDa M r complex, which is unable to bind to the receptor [19, 20] . These BPs are thought to regulate the action of IGF-I to its target tissue [19, 20] . The reported effects of these BPs on the IGF-I actions at the cellular level are conflicting [21] [22] [23] [24] . However, there is a general agreement that IGFBP-3 diminishes the actions of IGF-I when co-incubated with IGF-I and increases the actions of IGF-I when pre-incubated [23] . It has been shown in the latter case that IGFBP-3 bound to the membrane may facilitate the access of IGF-I to its cell surface receptors [23] . Little is known about the function or production of these IGFBPs by human articular chondrocytes [16] .
Failure of the anabolic response despite the high level of IGF-I in OA cartilage might result from decreased availability of IGF-I, due to BPs [16] . This study identifies which IGFBPs were produced and released from normal and OA human cartilage explants, and evaluates the role of IGF-I and IL-1 in modulating this synthesis. We further investigate the role of IGFBP-3 in modulating the anabolic effect of IGF-I on PG production. Our results show that both normal and OA human cartilage explants released a doublet of IGFBPs corresponding to different states of glycosylation of IGFBP-3. In the OA explants, pre-incubation with IGFBP-3 increased PG production only in cartilages which responded poorly or not at all to IGF-I action. These results suggest that the in vivo action of IGF-I during the OA process may be intimately regulated by the local level of IGFBP-3.
METHODS

Materials
Except when noted, all biochemicals were from Sigma Chemical Co. (St Louis, MO). Fetal calf serum was purchased from Gibco. Recombinant (r) human IGF-I, recombinant human IGFBP-3 (glycosylated form with a 45 kDa M r ) and recombinant human IL-l/f were from INC growth factor USA. Rabbit polyclonal antibody anti-human IGFBP-3 was from Eurodex, Souffelweyersheim, France (no cross-reactivity with other IGFBPs).
Human cartilage explant culture
Human cartilage was taken from 14 OA samples (mean age 69 yr) and two macroscopically normal cartilages (mean age 72 yr). Osteoarthritic cartilage was obtained from Addenbrookes Hospital (Cambridge, UK), after total joint replacement for advanced OA (knee or hip) [25] . Normal cartilage was obtained from osteophytes within the same joints and from femoral heads after hip prosthesis for femoral neck fracture. Cartilage slices were aseptically dissected and explanted into serum-free medium. Tissue was taken from the same area of each joint and only full-thickness cartilage served for the study. Cartilage covering the osteophytes, as well as the fibrous cartilage adjacent to the ebumated area, was usually avoided. Cartilage sections from explants were examined by toluidine blue dye staining. All OA cartilage samples showed less of PG relative to controls with characteristic OA pathology.
Cartilage explants (mean wet weight ~ 25 mg) were put into 24 well plates and covered with serum-free medium (Iscove's medium, Sigma Co., St Louis) supplemented with ascorbic acid (0.85 mM), glutamine (2 mM), penicillin (100 IU/ml) and kanamycin (100 IU/ ml), transferrin and bovine serum albumin (0.1%).
After culture in basal medium for 72 h, different growth factors and cytokines were added to the medium for a further 24-72 h. Most of the studies reported here were carried out with 100 ng of human rIGF-I. Human rIL-1/? was used at lOng/ml. All experiments were carried out in duplicate, comparing the effects of growth factors in the same cartilage from adjacent areas.
Some human cartilage explant samples were killed by freeze-thawing directly after the cartilage dissection in order to block protein synthesis. Thereafter, they were cultured under the same experimental conditions as described above. This was done to determine whether the binding proteins detected in the medium only resulted from passive release of proteins sequestered in the matrix.
Western ligand blotting and immunoblotting were performed on the harvested medium.
Western ligand blots
Conditioned medium samples were concentrated 10-fold by centrifugation in a Speed Vac. Western ligand blots were carried out according to the method of Hossenlopp et al. [26] . Briefly, samples were separated on the basis of size by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) under non-reducing conditions with 2 pi of fetal calf serum (FCS) as control. Proteins were then electrotransferred onto a nitrocellulose filter using a Biorad apparatus. The filters were washed in 3% NP 40 in Tris-buffered saline (TBS) for 30 min, and then incubated with 1% bovine serum albumin (BSA) in TBS for 2 h at +4°C with gentle shaking. Filters were washed in TBS-Tween (0.1%) for 10 min and then incubated with [ m I]IGF-I at 4°C, overnight (IGF-I was labelled with i2i l and final radioactivity was 2000 Ci/ mmol). Filters were washed successively in TBS-Tween for 15 min and then in TBS (three times). The filters were visualized by autoradiography. Autoradiographs were analysed by scanning laser densitometry (Ultroscan Laser densitometer, LKB instruments).
Results are expressed as the amount of IGFBPs relative to milligrams of tissue or to DNA content.
Immunoblots
Aliquots of cartilage explant medium samples were separated by PAGE by the method of Laernmli on a 10% gel under non-reducing conditions, and proteins were electrotransferred onto a nitrocellulose sheet in Tris-glycine buffer containing 10% methanol (pH 8.3) for 24 h at 4°C. The nitrocellulose sheets were saturated with 5% BSA in Tris-buffered saline (pH 7.6) for 30 min at 37°C and then incubated for 1 h with 1:500 polyclonal antibody anti-human IGFBP-3 (Eurodex, Souffelweyersheim, France). After washing in TBSTween buffer (0.05 M Tris-HCl, 0.15 M NaCl, pH 7.4), antibodies were detected using a biotinylated goat anti-rabbit immunoglobulin G (diluted 1/1000) for 30 min. Sections were then washed and incubated with 1:50 streptavidin-biotinylated alkaline phosphatase complex (Dako kit), for 45 min at room temperature. Immunoreactivity was revealed by the addition of a chromogenic substrate consisting of naphtbol and fast-red solution, containing levamisole that gives a red to brown staining. Controls, performed without anti-IGFBP-3 polyclonal antibody, were all negative.
DNA assays
Chondrocyte DNA was quantified as follows: 200 fil of papain-digested sample (as for proteoglycan synthesis) were mixed with 200 /il of RNase in LP3 tubes and incubated at 37°C for 30 min. Ethidium bromide was added just before reading. The fluorescence was determined on a spectrophometer (excitation wavelength of 540 nm, emission wavelength 580 nm). Calf thymus DNA was used as standard, and its concentration was confirmed by absorbance at 260 nm.
Proteoglycan synthesis
The synthesis of PG was studied after a pulse of "SOJ". Briefly, cartilage explants stimulated with IGF-I (24-48 h) were incubated in the presence of radiolabelled 35 SO 4 during a 16 h pulse. The medium was removed and cartilage explants were then washed three times with ice-cold phosphate-buffered saline (PBS) containing non-labelled sulphate. The cartilage was digested in a buffer [KH 2 PO 4 (200 mM), NaH 2 PO 4 , pH 6] containing 0.5% papain (10-20 U/mg), EDTA (0.05 M), JV-acetylcysteine (0.03%) and heated at 65°C for 3 h. Digestion was stopped when the whole cartilage was solubilized. Twenty microlitres of the digest were applied to filter paper and air dried. Glycosaminoglycans were precipitated with cetylpyridinium chloride (CPC). Briefly, filter papers were first washed in 1 % CPC during 30 min and then washed twice in 0.1 % CPC during 5 min, and finally dried overnight. The "SO 4 radioactivity was measured by liquid scintillation counting using a 35 SO 4 protocol reading on a Beckman scintillation counter. Results were calculated from the M SO 4 incorporation rate and the specific activity was normalized to the dry weight of the cartilage sample. In IGF-I-stimulated experiments, the PG synthesis was expressed as a percentage of the control (referred to as 100%).
Study of the effects of rIGFBP-3 on PG synthesis
Regulation of PG synthesis by IGF-I was studied in the presence of rIGFBP-3 (equimolar concentration with IGF-I, 1:4) in two ways: in one set of experiments, rIGFBP-3 was co-incubated with IGF-I for 24 h; in another set of experiments, the samples were pre-incubated with rIGFBP-3 for 24 or 72 h before adding IGF-I for 24 h. In both experiments, cartilage explants without added growth factors, with IGF-I alone (lOOng/ml) and with rIGFBP-3 alone (equimolar concentration) served as controls. Results compared IGF-I plus rIGFBP-3 to IGF-I alone, and are 
Statistical analysis
The difference between the effects of the growth factors was established using one-way analysis of variance.
RESULTS
Release of the IGFBPs by human cartilage explants
Explants of OA human cartilage, when cultured for 72 h in basal media, constitutively released an IGFBP doublet with a molecular mass of 39/43 kDa (Fig. 1) . Conditioned medium from cultures of age-matched non-OA human cartilage taken following femoral neck fracture or from osteophytes within the same OA joints contained barely detectable amounts of IGFBP of the same size. Analysis of Western ligand blots using laser densitometry to scan the autoradiographs indicated 50-to 160-fold higher production of the 39 kDa IGFBP from cartilage showing histology characteristic of OA pathology compared to histologically normal-looking cartilage. Although more binding protein was always produced by OA explants, there was a wide variation in the amounts obtained in the different OA joints (from 500 to 2500 U/mg). Production of the IGFBP doublet from OA cartilage as a function of time is shown in Fig. 2 . Maximum levels (expressed relative to DNA) were detected in the culture medium for the first 4 days, and thereafter decreased to 20% of this value on days 5 and 6, and to < 10% from day 7. Conditioned medium from OA cartilage explants that had been frozen-thawed prior to culture contained no detectable IGFBP (data not shown), indicating that increased release of BP into the medium was due to increased de novo synthesis and not from passive diffusion of material stored in the matrix. The size and pattern of secretion of IGFBP with time were similar in all OA and normal explants tested, the main difference being the total amounts produced. In some OA samples, a band around 30 kDa was detectable.
Modification of IGFBP production by IGF-I and IL-1
A dose-dependent increase in the production of IGFBP (relative to milligrams) was obtained when OA cartilage was cultured with IGF-I: six times basal levels at 50 ng/ml IGF-I and 20 times basal levels at lOOng/ml (Fig. 3) . This is comparable to the increase of 20-fold detected for non-OA cartilage cultured with IGF-I (100 ng/ml) (Fig. 3) . IL-1 (10 ng/ml) alone induced a slight but similar stimulation of ~ 2-fold in both OA and normal explants.
Identification of human cartilage IGFBP
The molecular size of the IGFBP secreted from human cartilage co-migrated on the SDS gels with IGFBP-3 in samples of FCS (data not shown). Antibody to human IGFBP-3 was used to confirm this by Western blot analysis of the same samples. Figure 4 shows that the IGFBP detected in conditioned medium from OA and normal cartilage reacts positively with IGFBP-3 antiserum. The increased amounts of BP produced by stimulation with IGF-I and IL-1 were also identified as IGFBP-3.
Effect of rIGFBP-3 on proteoglycan synthesis
The rate of PG synthesis in cultured OA explants on average was 2.6-fold less than that in normal cartilage. Normal senescent cartilage explants only weakly responded to IGF-I action. Cartilage explants from different OA joints varied considerably both in the basal rate of PG synthesis and in their response to IGF-I (Fig. 5 ). Those with a higher initial base rate of PG synthesis (13000 ± 1500 d.p.m./mg) showed much less stimulation with IGF-I (33 ± 15%) (n = 4) and were designated as low responders. Those showing the lowest basal rates of PG synthesis (7200 ± 1700 d.p.m./ mg) gave the greatest stimulation with 100 ng/ml IGF-I (+180 ± 34%) (n = 3) and were designated as high responders. There were some epidemiological differences between the two groups. The low-responder group consisted mainly of patients (all men) with hip OA (only one knee joint), with a mean age of 71 yr (± 8). The high-responder group consisted of patients with knee OA, except for one hip joint, with a mean age of 66yr(±10). Co-incubation of the explants with equimolar amounts of IGF-I and rIGFBP-3 (1:4 w/w) together made no difference to the rate of PG synthesis in either OA group or in the normal cartilage. Pre-incubation of the low-responder OA group with IGBP-3 alone for 72 h enhanced the IGF-I-stimulated PG synthesis by 70%, whereas no effect was detected with a shorter pre-incubation time of 24 h. Pre-incubation of the high-responder OA group for 24 or 72 h with IGBP-3 did not increase PG synthesis further. Pre-incubation of the non-OA cartilage with IGFBP-3 for 24 or 72 h enhanced IGF-I-stimulated PG synthesis by 50 and 30%.
There was no apparent difference in the histological appearance or toluidine blue staining of OA cartilage in the low-and high-responder groups.
DISCUSSION
The primary result of this study is to show that cultured human OA cartilage mainly produces a doublet of IGFBP, in keeping with the molecular weight of IGFBP-3, which in turn can modulate the action of IGF-I on PG synthesis in some OA cartilage samples classified as low responders to IGF-I.
We have deliberately chosen explant rather than chondrocyte cell cultures in this study, for two main reasons: (i) culture of chondrocytes in monolayers can result in differentiation of the phenotype towards fibroblasts [27] ; (ii) chondrocytes cultured in agarose or alginate beads produce only very low levels of IGFBPs (data not shown) [28] .
Human normal and OA cartilage explants released a doublet of IGFBPs with a 39-43 kDa M,, in keeping with the differentially glycosylated forms of IGFBP-3 [23] . Western immunoblots confirmed that this 39/43 kDa doublet corresponded to IGFBP-3. The unglycosylated IGFBP3 was not detected. The 39 kDa IGFBP production was increased in OA cartilage compared to normal tissue. The production of IGFBPs by articular chondrocytes varies with the mode of culture and the species, and may explain the differences observed in the literature. In culture medium of young rabbit chondrocytes, a major IGFBP with a 30 kDa M, is present [29] . However, in this study, chondrocytes were cultured with a high dose of fibroblast growth factor (FGF) [29] , which has been shown to modulate IGFBP synthesis [30] . IGFBPs with M, of 24, 29, 33 and 39/45 kDa were identified in medium from adult bovine articular chondrocytes cultured at high density and stimulated with IGF-I [28] . In agreement with our results, Dore et al. [16] found that human OA chondrocytes plated at high density mostly released a 43/37 kDa doublet corresponding to IGFBP-3 and, to a minor extent, IGFBPs of 33, 25 and 23 kDa.
Both IGF-I and IL-1 increased the release of this doublet from OA cartilage explants by 20-and 2-fold, respectively, compared with controls. Increased production of IGFBPs under IGF-I stimulation has been noticed previously in several cell lines [31] [32] [33] . It may act through an upregulation of IGFBP-3 mRNA level [34, 35] or independently of an increase in IGFBP-3 mRNA, by an IGF-I receptor-independent mechanism [19] . Our finding of increased amounts of IGFBP-3 in culture medium under IL-1 stimulation is more intriguing. It may be due to an increased proteolytic activity, that may release the IGFBP-3 entrapped into the matrix. However, similar results have been found in cultured rat articular chondrocytes, suggesting a direct effect of IL-1/? on IGFBP synthesis [36] . Therefore, IL-1 may interfere with IGF-I action through modulation of IGFBP secretion. Other growth factors, such as transforming growth factor (TGF) /?, have also been shown to regulate IGFBP-3 production [37, 38] .
IGFBP-3 has the capacity to modulate PG synthesis induced by IGF-I. In functional studies, among the OA cartilage explants, we identified two kinds of responses: one group (l°w responders) weakly responded to IGF-I, while the other group (high responders) dramatically responded to IGF-I stimulation. Previous reports focus on the refractory response of damaged cartilage (arthritic) in terms of PG synthesis under IGF-I stimulation [10, 16, 18] . The difference that we observed between the low and the high responders may be in part explained by several factors: (i) the low-responder group corresponds to patients with hip OA, except for one case of knee OA, while in the high-responder group all correspond to OA of the knee, except for one case of hip OA; (ii) hip cartilages appeared more severely damaged than knee cartilages; (iii) patients in the low-responder group were older (mean age 71 ± 8 yr) than in the high-responder group (66.6 ±10 yr). This heterogeneity in cartilage specimens may account for the observed difference. A recent study shows that the response of human articular chondrocytes to growth factors is highly dependent on the age of the donors [39] . Moreover, the difference between human cartilage may also be related to a difference in IGF-I production, since OA cartilages produce more IGF-I, notably in severely damaged tissues [14] .
In the presence of rIGFBP-3, our results show that: (i) in normal cartilage explants, co-incubation of IGF-I with rIGFBP-3 does not influence PG synthesis, but pre-incubation for 24 or 72 h prior to IGF-I treatment induces, respectively, a 50 and 30% increase in PG synthesis; (ii) in low-responder OA cartilage, after 72 h but not at 24 h, pre-incubation with IGFBP-3 markedly potentiates the IGF-I stimulation of PG synthesis (+70%); (iii) neither co-incubation nor pre-incubation for 24 or 72 h induces significant changes in PG synthesis in the high-responder group.
There is increasing evidence to suggest that IGFBPs can modify the actions of IGFs on various tissues. The affinity of IGF-I for BP-3 (glycosylated or nonglycosylated form) was found to be higher than for the type 1 receptor [40] . When IGFBP-3 is co-incubated with IGF-I, it may sequester the growth factors, preventing receptor interaction, and as a consequence downregulate its metabolic and mitogenic actions [22, 23, 41, 42] . However, in our experiment using cartilage explants, we did not observe any change in PG synthesis when IGF-I was co-incubated with IGFBP-3. Similarly, in bovine cartilage explants, Tesh et al. [24] have shown that when IGF-I is complexed with binding proteins, the rate of PG synthesis is maintained for 5 days of culture, and then decreases. One explanation could be that the BP/IGF complex is unable to penetrate into the cartilage matrix. However, IGF/BP complexes can be dissociated in the presence of highly negatively charged macromolecules, such as heparin or with proteinases [43] (which are present within the matrix and in the synovial fluid), leaving IGF-I free [44] . Some authors have reported a potentiation of IGF-I action when complexed with its IGFBPs [21] . Part of the discrepancy in these results may be directly related to the endogenous levels of IGFBP-3, which is constitutively secreted by some but not all cell lines [45] .
In the low OA responder group, pre-incubation with IGFBP-3 enhances the IGF-I PG synthesis response, as has been reported with pHJthymidine incorporation into human and bovine fibroblast cultures [23, 46] . Further study has shown (by cross-linking analysis) that the potentiating effect of IGFBP-3 pre-incubation is associated with an increase in IGF-I binding to membrane-associated IGFBP-3 rather than to the type 1 receptor [39] . The mechanism of IGFBP-3 attachment to the membrane is not understood, nor is the mechanism that accounts for cell-bound IGFBP-3-induced potentiation of IGF cellular action. IGFBP-3 attached to the membrane might orientate and facilitate IGF-I binding to the receptor (type 1 or another receptor) [47] , promote receptor aggregation or prevent the downregulation of IGF-I type 1 receptor induced by IGF-I, and therefore prolong the effects of IGF-I [45] . On the other hand, the level of cell-bound IGFBP is dependent on IGF-I stimulation and decreases following IGF-I stimulation [48] .
The consensus of these various reports is that the cell surface-associated IGFBPs can enhance the IGF-I action, while the IGFBPs free in the medium inhibit IGF-I action. Distribution of free IGFBPs between the medium or extracellular matrix and the cell membrane could determine the bioavailability of IGF-I. Thus, the difference in IGF-I sensitivity that we observed between our OA cartilage specimens might result from an 'in situ' ratio between free IGFBP-3 and cell-bound IGFBP-3. Modulation of IGF-I action by its IGFBP-3 provides new insights to explain the refractory response to IGF-I of arthritic cartilages [10, 16] . In the high-responder group, one may hypothesize the presence of a high level of cell-bound IGFBP-3, which could not be further increased by added BP. On the contrary, in the low-responder group, low levels of cell-bound IGFBP-3 might explain a failure of IGF-I action which can be corrected following sufficient exposure time to IGFBP-3 prior to IGF-I, thereby potentiating the IGF-I action.
Other factors may influence the availability of IGFBPs. Local levels of IGFBP-3 protease especially could limit the action of the IGFBP-3 [49] , although it is not known whether such serine proteases are present within the damaged cartilage.
In conclusion, increased IGFBP-3 in conditioned medium from OA cartilage could be related to the lower PG synthesis seen in the majority of OA tissues, if IGFBP-3 is inhibitory to the action of IGF-I. On the contrary, pre-incubation with IGFBP-3 induces, in some circumstances, an enhancement of PG synthesis. This apparent paradox may relate to surface or matrix association of IGFBP-3 pre-incubated with explants.
